Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Vascular and Interventional Radiology

• Publication date

  2011-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jvir.2011.07.002PMID 21849247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prospective Randomized Comparison of Chemoembolization with Doxorubicin-Eluting Beads and Bland Embolization with BeadBlock for Hepatocellular Carcinoma

  2010cited by this paper
• Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)

  2010cited by this paper
• Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies.

  2009cited by this paper
• Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study.

  2009cited by this paper
• Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy.

  2009cited by this paper
• Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

  2008cited by this paper
• Transarterial Chemoembolization of Unresectable Hepatocellular Carcinoma with Drug Eluting Beads: Results of an Open-Label Study of 62 Patients

  2008cited by this paper
• Design and endpoints of clinical trials in hepatocellular carcinoma.

  2008cited by this paper
• Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma.

  2007cited by this paper
• Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

  2007cited by this paper
• Prediction of Viable Tumor in Hepatocellular Carcinoma Treated With Transcatheter Arterial Chemoembolization: Usefulness of Attenuation Value Measurement at Quadruple-phase Helical Computed Tomography

  2007cited by this paper
• DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization.

  2006cited by this paper
• New Intra-arterial Drug Delivery System for the Treatment of Liver Cancer: Preclinical Assessment in a Rabbit Model of Liver Cancer

  2006cited by this paper
• Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy.

  2006cited by this paper
• Completeness of Treatment in Hepatocellular Carcinomas Treated With Image-guided Tumor Therapies: Evaluation of Positive Predictive Value of Contrast-enhanced CT with Histopathologic Correlation in the Explanted Liver Specimen

  2006cited by this paper
• Accuracy of Staging as a Predictor for Recurrence After Liver Transplantation for Hepatocellular Carcinoma

  2006cited by this paper
• Management of hepatocellular carcinoma

  2005cited by this paper
• Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.

  2004cited by this paper
• Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

  2003cited by this paper
• Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors.

  2002cited by this paper
• Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

  2002cited by this paper
• Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

  2002cited by this paper
• Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome.

  2001cited by this paper
• Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

  2001cited by this paper
• Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80)

  2000cited by this paper
• Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma

  2000cited by this paper

• S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion

  2025cites this paper
• Ethiodized Oil-based Transarterial Chemoembolization for Hepatocellular Carcinoma: Randomized Clinical Trial of Anhydrous Cisplatin Suspension versus Cisplatin Emulsion.

  2025cites this paper
• Spectrum of therapeutic options in hepatocellular carcinoma

  2025cites this paper
• Contrast-enhanced Ultrasound LI-RADS for Nonradiation Treatment Response Assessment in Liver Tumor: A Pictorial Review Based on LR-TR v2024

  2025cites this paper
• S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Kurzversion

  2025cites this paper
• S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Kurzversion

  2025cites this paper
• S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion

  2025cites this paper
• EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.

  2024cites this paper
• Comparison of Chemoembolization Outcomes Using 70–150 µm and 100–300 µm Drug-Eluting Beads in Treating Small Hepatocellular Carcinoma: A Korean Multicenter Study

  2024cites this paper
• 5-Fluorouracil combined with CalliSphere drug-eluting beads or conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score weighting analysis

  2024cites this paper
• Combination of Doxorubicin and Antiangiogenic Agents in Drug-Eluting Beads: In Vitro Loading and Release Dynamics in View of a Novel Therapeutic Approach for Hepatocellular Carcinoma

  2024cites this paper
• Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma

  2024cites this paper
• Efficacy and safety of transhepatic arterial chemoembolization with drug-loaded microspheres in unresectable primary liver cancer

  2024cites this paper
• Amount of ascites impacts survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization advocating for volumetric assessment

  2024cites this paper
• AI-derived body composition parameters as prognostic factors in patients with HCC undergoing TACE in a multicenter study

  2024cites this paper
• Comparative Study of the Short-Term Efficacy and Safety between DEB-TACE and C-TACE in the Treatment of Unresectable Hepatocellular Carcinoma, a Retrospective Study

  2024influential citation
• Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a prospective study

  2023cites this paper
• S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion

  2023cites this paper
• Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association

  2023cites this paper
• 中咽頭癌N0症例の経口的ロボット支援手術における術中術後出血予防目的の経カテーテル動脈塞栓術

  2023cites this paper
• 2022 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for Transarterial Therapy of Hepatocellular Carcinoma: What’s New?

  2023cites this paper
• S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0

  2023cites this paper
• Efficacy and complications of transarterial chemoembolization alone or in combination with different protocols for hepatocellular carcinoma: A Bayesian network meta-analysis of randomized controlled trials

  2023cites this paper
• Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada.

  2023cites this paper
• S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion

  2023cites this paper
• Effective Utilization of Conventional Transarterial Chemoembolization and Drug-eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma: A Guide to Proper Usage

  2023cites this paper
• S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion

  2023cites this paper
• Bland Embolization and Transarterial Chemoembolization in Hepatocarcinoma

  2023cites this paper
• S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0

  2023cites this paper
• Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association

  2023cites this paper
• Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study

  2023cites this paper
• Drug-eluting beads versus conventional transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis

  2023cites this paper
• Local tumor control of intermediate and advanced stage hepatocellular carcinoma after local ablative treatment with image-guided interstitial high-dose-rate brachytherapy: A subgroup analysis of 286 HCC nodules.

  2023cites this paper
• Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma

  2022cites this paper
• Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems

  2022cites this paper
• Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC

  2022cites this paper
• DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study

  2022cites this paper
• Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?

  2022cites this paper
• Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma—A Propensity Score Weighted Comparison of Efficacy and Safety

  2022cites this paper
• MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View

  2022cites this paper
• Transarterielle Chemoembolisation des hepatozellulären Karzinoms

  2022cites this paper
• 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

  2022cites this paper
• The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study

  2022cites this paper
• 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

  2022cites this paper
• 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

  2022cites this paper
• S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms

  2022cites this paper
• Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)

  2022cites this paper
• Proteoglycan-4 predicts good prognosis in patients with hepatocellular carcinoma receiving transcatheter arterial chemoembolization and inhibits cancer cell migration in vitro

  2022cites this paper
• Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302

  2022cites this paper
• Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations

  2022cites this paper
• Recent Trends and In-Hospital Mortality of Transarterial Chemoembolization (TACE) in Germany: A Systematic Analysis of Hospital Discharge Data between 2010 and 2019

  2022cites this paper
• Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study

  2022cites this paper
• Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma

  2021cites this paper
• A Comparison of Adverse Events Among Radiofrequency Ablation, Conventional Transarterial Chemoembolization (TACE) and Drug-Eluting Bead TACE in Treating Hepatocellular Carcinoma Patients

  2021cites this paper
• Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function

  2021cites this paper
• The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment

  2021cites this paper
• Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial

  2021cites this paper
• Paradigm shift in the treatment options of hepatocellular carcinoma

  2021cites this paper
• Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?

  2021cites this paper
• Prospective Multi-Center Korean Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolics for Nodular Hepatocellular Carcinoma: A Two-Year Outcome Analysis

  2021cites this paper
• Efficacy of Superselective Conventional Transarterial Chemoembolization Using Guidance Software for Hepatocellular Carcinoma within Three Lesions Smaller Than 3 cm

  2021cites this paper
• Impact of cone-beam computed tomography with automated feeder detection software on the survival outcome of patients with hepatocellular carcinoma during treatment with conventional transarterial chemoembolization

  2021cites this paper
• Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma

  2021cites this paper
• Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads

  2021cites this paper
• Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

  2021cites this paper
• CMAR_A_308097 5373..5382

  2021cites this paper
• Callispheres® Drug-Eluting Beads Transarterial Chemoembolization Might be an E�cient and Safety Down-Staging Therapy in Unresectable Liver Cancer Patients

  2021cites this paper
• Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis

  2021cites this paper
• CMAR_A_328812 6935..6941

  2021cites this paper
• Increased Liquefactive Necrosis Formation After Transarterial Chemoembolization Combined with Molecular Targeted Agents Plus Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

  2021cites this paper
• Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model

  2021cites this paper
• Interventional neuro-oncology.

  2021cites this paper
• Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

  2021cites this paper
• Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients

  2021cites this paper
• Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice

  2020cites this paper
• Robotic Devices for Minimally Invasive Endovascular Interventions: A New Dawn for Interventional Radiology

  2020cites this paper
• Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization

  2020cites this paper
• Advances in the treatment of hepatocellular carcinoma using drug-eluting beads

  2020cites this paper
• Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.

  2020cites this paper
• Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.

  2020cites this paper
• Treatment Strategy of Transarterial Chemoembolization for Hepatocellular Carcinoma

  2020cites this paper
• Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.

  2020cites this paper
• Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years?

  2020cites this paper
• Liver and Bile Duct Cancer

  2020cites this paper
• Locoregional Therapies in the Treatment of 3- to 5-cm Hepatocellular Carcinoma: Critical Review of the Literature.

  2020cites this paper
• Single-center randomized trial comparing conventional chemoembolization versus doxorubicin-loaded polyethylene glycol microspheres for early- and intermediate-stage hepatocellular carcinoma

  2020cites this paper
• Correction: Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review

  2020cites this paper
• Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review

  2020cites this paper
• A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials

  2020cites this paper
• Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients

  2020cites this paper
• Comparative Analysis of Safety and Efficacy of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma in Patients with and without Pre-Existing Transjugular Intrahepatic Portosystemic Shunts.

  2020cites this paper
• Interventional radiology for liver diseases

  2020cites this paper
• Transarterial chemoembolization using callispheres beads in hepatocellular carcinoma therapy

  2020cites this paper
• 3D Printed Absorber for Capturing Chemotherapy Drugs before They Spread through the Body

  2019cites this paper
• Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards.

  2019cites this paper
• Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma

  2019cites this paper
• Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC)

  2019cites this paper
• Trends in Interventional Radiology Through the Eye of the Journal of Vascular and Interventional Radiology: A 27-Year History.

  2019cites this paper
• Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma.

  2019cites this paper
• Role of drug-eluting beads versus conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma

  2019cites this paper